Stockscreener 앱 받기
3.89
1.27%
-0.05
전일 마감가:
$3.94
열려 있는:
$3.92
하루 거래량:
18,742
Relative Volume:
0.36
시가총액:
$1.38B
수익:
$842.96M
순이익/손실:
$-185.63M
주가수익비율:
-7.3968
EPS:
-0.5259
순현금흐름:
$-228.52M
1주 성능:
-2.99%
1개월 성능:
+14.08%
6개월 성능:
+27.12%
1년 성능:
+24.68%
1일 변동 폭
$3.88
$3.9465
1주일 범위
$3.8692
$4.0592
52주 변동 폭
$2.84
$5.6405
Evotec Se Adr Stock (EVO) Company Profile
EVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
3.88 | 1.40B | 842.96M | -185.63M | -228.52M | -0.5259 |
|
ZTS
Zoetis Inc
|
141.79 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.81 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.015 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.80 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
443.62 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-24 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-10-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-08-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-07-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-04-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-06-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-04-04 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-11-16 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | 재개 | Cowen | Outperform |
| 2022-01-07 | 재개 | Citigroup | Neutral |
모두보기
Evotec Se Adr 주식(EVO)의 최신 뉴스
Evotec (NASDAQ:EVO) versus CASI Pharmaceuticals (NASDAQ:CASI) Critical Survey - Defense World
Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen - Benzinga
Evotec Ag’s Earnings Call: Mixed Sentiments and Strategic Moves - MSN
Annual General Meeting - Evotec
Stock Information - Evotec
Evotec SE ADR earnings missed by $0.07, revenue fell short of estimates - Investing.com South Africa
Evotec AG Reports Mixed H1 2025 Performance - TipRanks
Ørsted announces plan for a rights issue with support from the Danish State as majority shareholder and gross proceeds of DKK 60 billion11.08.25NewsARIVA.DE - rova
Evotec shares drop sharply after lowering 2025 revenue forecast - MSN
Evotec and Sandoz plan potential sale of Toulouse biologics site By Investing.com - Investing.com South Africa
Evotec and Sandoz plan potential sale of Toulouse biologics site - Investing.com
Evotec SE (EVO) Stock Forecasts - Yahoo Finance
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union - Ariva
SAP Quarterly Statement Q2 202522.07.25News - Ariva
Evotec stock tumbles after slashing 2025 revenue guidance - Investing.com Australia
Evotec stock tumbles after slashing 2025 revenue guidance By Investing.com - Investing.com Canada
8 New 4-Star Stocks - Morningstar
Evotec SE ADR (EVO) Strikes $4.73: The Risk Seems Worthwhile At This Price - Stocksregister
Evotec SE ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com Nigeria
Evotec Ag Earnings Call: Mixed Sentiment Amid Growth - TipRanks
Evotec AG Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Evotec shares surge 51% following InvestingPro’s undervalued signal By Investing.com - Investing.com
Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com Australia
Evotec SE Reports Strong Q4 2024 and New Strategy - TipRanks
Evotec Ag’s Earnings Call: Growth Amid Challenges - TipRanks
Evotec: Management Streamlines Strategy to Refocus on Core Strengths Amid Biologics Momentum - Morningstar
Bayer, BioNxt Solutions, Evotec – falscher Zoll Alarm bei Pharma und Biotech! Welche Aktien lohnen sich? - kapitalerhoehungen.de
Evotec: Some Recovery Has Come, But Much More Is Expected - Seeking Alpha
Markets Brief: Are Bank Stocks Expensive? - Morningstar
Evotec SE withdraws acquisition offer - Investing.com
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - Baystreet.ca
Evotec Se Adr (EVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
0.78%
자본화:
|
볼륨(24시간):